České esperantské fórum - Ĉeĥa esperanta diskutejo
Astra says AZD7442 is ineffective in preventing and treating symptomatic coronavirus - Verze k tisku

+- České esperantské fórum - Ĉeĥa esperanta diskutejo (http://forum.esperanto.cz)
+-- Fórum: Česká esperantská komunita (/forumdisplay.php?fid=4)
+--- Fórum: Jazyková poradna (/forumdisplay.php?fid=9)
+--- Téma: Astra says AZD7442 is ineffective in preventing and treating symptomatic coronavirus (/showthread.php?tid=75395)



Astra says AZD7442 is ineffective in preventing and treating symptomatic coronavirus - limited - 17-06-2021 06:43 AM

[Obrázky: 20210105_Canva_COVID4-768x432.png]



British company AstraZeneca announced on Tuesday (June 15) that it had tested positive for COVID-19. Monoclonal สล็อต antibody therapy has yet to meet the primary goal of preventing and treating illness in people at risk of contracting COVID-19. The revelation has shattered hopes about the prevention and treatment of COVID-19. for those who have not been vaccinated


Astra announces that AZD7442, a drug for the prevention and treatment of COVID-19 The monoclonal antibody Reduce the risk of contracting COVID-19 Only 33% of the symptoms were present among those at risk of contracting COVID-19. All, including those who test negative after contact with an infected person. compared to placebo which Astra is statistically insignificant.

Astra has collected that data from the company's Phase 3 trials in adults over 18 years of age who have not been vaccinated. and were confirmed to have been in contact with a person infected with COVID-19 within the eight days prior to participating in the trial.


However, AZD7442 was 92% effective in preventing symptomatic COVID-19 compared with placebo among participants who tested negative after coming into contact with an infected person. This indicates that AZD7442 may be effective in preventing the development of COVID-19. symptomatic in people who have not yet been infected


Astra states that The company will continue to trial AZD7442 in other trials.


Dr Myron J. Levin, the trial's principal investigator, said the drug AZD7442 may be effective in preventing the development of COVID-19. with symptoms only in those who have not been infected and added that “While efforts to vaccinate against COVID-19 that success But there is still a huge need for alternatives to prevent and treat COVID-19. For certain populations, including those who cannot be vaccinated. or who may have an inadequate immune response from vaccination.”